US gene-editing firm eGenesis closes $125m in Series C round dealstreetasia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dealstreetasia.com Daily Mail and Mail on Sunday newspapers.
eGenesis raises US$125m in Series C financing to ‘transform’ transplant medicine The gene-editing and genome-engineering company, eGenesis, today announced the completion of a US$125m Series C financing round.
The Cambridge, Massachusetts biotech, which is using gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, said proceeds will be used to bring its lead programs in kidney and islet cell transplant into human proof-of-concept studies.
In addition, the capital will go towards the continued development of its gene-editing platform and scaling of GMP production.
Srini Akkaraju, founder and managing general partner at Samsara BioCapital, one of the investors in the round, said the work eGenesis is doing in kidney and islet cell transplants could address the fast-growing unmet need for patients with kidney failure and type 1 diabetes.